{
    "clinical_study": {
        "@rank": "136280", 
        "arm_group": {
            "arm_group_label": "Afatinib", 
            "arm_group_type": "Experimental", 
            "description": "patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability"
        }, 
        "brief_summary": {
            "textblock": "The main aim of this study is to evaluate the safety and tolerability of afatinib in\n      patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring\n      EGFR mutation(s) and have never been treated with an EGFR-TKI"
        }, 
        "brief_title": "Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)\n\n          2. Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the\n             institution's testing methodology\n\n          3. Male or female patients age >=18 years\n\n          4. Adequate organ function, defined as all of the following:\n\n               1. Absolute neutrophil count (ANC) >1500/mm3\n\n               2. Platelet count>75,000/mm3\n\n               3. Serum creatinine<1.5 times of the upper limit of normal and/or creatinine\n                  clearance (measured or calculated)>45ml/min\n\n               4. Total bilirubin <1.5 times upper limit of (institutional) normal\n\n               5. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) < three\n                  times the upper limit of (institutional) normal (if related to liver metastases\n                  < five times ULN)\n\n          5. Eastern Cooperative Oncology Group (ECOG)  score between 0-2\n\n          6. Written informed consent by patient or guardian prior to admission into the trial\n             that is consistent with International Conference on Harmonization (ICH)- Good\n             Clinical Practice (GCP) guidelines and local law\n\n        Exclusion criteria:\n\n          1. Prior treatment with an EGFR tyrosine kinase inhibitor (TKI)\n\n          2. Hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment\n             (continued use of anti-androgens and/or gonadorelin analogues for treatment of\n             prostate cancer permitted)\n\n          3. Radiotherapy within 14 days prior to drug administration, except as follows:\n\n               1. Palliative radiation to organs other than chest may be allowed up to 2 weeks\n                  prior to drug administration, and\n\n               2. Single dose palliative treatment for symptomatic metastases outside above\n                  allowance to be discussed with sponsor prior to enrolling\n\n          4. Major surgery within 4 weeks before starting trial treatment or scheduled for surgery\n             during the projected course of the trial\n\n          5. Known hypersensitivity to afatinib or any of its excipients\n\n          6. History or presence of clinically relevant cardiovascular abnormalities such as\n             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)\n             classification of 3, unstable angina or poorly controlled arrhythmia as determined by\n             the investigator. Myocardial infarction within 6 months prior to starting trial\n             treatment\n\n          7. Women of Child-Bearing Potential (WOCBP) and men who are able to father a child,\n             unwilling to use adequate contraception prior to trial entry, for the duration of\n             trial participation and for at least 2 weeks after treatment has ended\n\n          8. Childbearing potential who:\n\n               1. are nursing or\n\n               2. are pregnant or\n\n               3. are not using an acceptable method of birth control, or do not plan to continue\n                  using this method throughout the trial and/or do not agree to submit to\n                  pregnancy testing required by this protocol\n\n          9. Any history of or concomitant condition that, in the opinion of the investigator,\n             would compromise the patients ability to comply with the trial or interfere with the\n             evaluation of safety for the trial drug\n\n         10. Previous or concomitant malignancies at other sites, except effectively treated\n             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ\n             or effectively treated malignancy that has been in remission for more than 3 years\n             and is considered to be cured\n\n         11. Requiring treatment with any of the prohibited concomitant medications that cannot be\n             stopped for the duration of trial participation\n\n         12. Known pre-existing interstitial lung disease\n\n         13. Presence of poorly controlled gastrointestinal disorders that could affect the\n             absorption of the trial drug (e.g. Crohn\u00bfs disease, ulcerative colitis,\n             malabsorption, or CTC grade =2 diarrhea of any aetiology) based on investigator\n             assessment\n\n         14. Active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg and/or\n             HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C RNA)\n             and/or known Human Immunodeficiency Virus (HIV) carrier\n\n         15. Meningeal carcinomatosis\n\n         16. Symptomatic brain metastases (patients with asymptomatic brain metastases, who were\n             previously treated, are eligible provided they have had Stable Disease (SD) for at\n             least 4 weeks on stable doses of medication)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044380", 
            "org_study_id": "1200.48"
        }, 
        "intervention": {
            "arm_group_label": "Afatinib", 
            "description": "40, 30, or 20mg tablets taken once daily, dosage depending on tolerability", 
            "intervention_name": "Afatinib", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Burnaby", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "1200.48.00010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "1200.48.00001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barrie", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1200.48.00003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1200.48.00009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newmarket", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1200.48.00007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1200.48.00002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1200.48.00004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1200.48.00008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events according to Common Terminology Criteria (CTCAE Version 3).", 
            "safety_issue": "No", 
            "time_frame": "89 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}